Abstract:
The introduction of effective highly active antiretroviral therapy (HAART) in the mid 1990s lead to the marked reduction in the morbidity and mortality from human immunodeficiency virus (HIV) infection. Increasing life expectancy, an aging population, and high rates of smoking have lead to concerns of the health of HIV infected individuals in the long run. Metabolic effects of HIV infection such as hypertriglyceridemia are well defined and side effects of HAART such as dyslipidemia and were described soon after its introduction.
